Exclusive: Formation Bio raised a $372M Series D last year.
Later today, the New York biopharma will announce its first licensing deal since raising that money — bringing in a CD226 antibody from the Spanish biotech IMIDomics.
My latest for @endpts.com: endpoints.news/exclusive-fo...
Later today, the New York biopharma will announce its first licensing deal since raising that money — bringing in a CD226 antibody from the Spanish biotech IMIDomics.
My latest for @endpts.com: endpoints.news/exclusive-fo...
Exclusive: Formation licenses first drug since $372M raise, eyes more deals in 2025
Formation Bio licenses first-in-class anti-CD226 antibody from IMIDomics for IBD treatment, marking first drug acquisition since $372M Series D raise in 2023.
endpoints.news
July 29, 2025 at 12:20 PM
Exclusive: Formation Bio raised a $372M Series D last year.
Later today, the New York biopharma will announce its first licensing deal since raising that money — bringing in a CD226 antibody from the Spanish biotech IMIDomics.
My latest for @endpts.com: endpoints.news/exclusive-fo...
Later today, the New York biopharma will announce its first licensing deal since raising that money — bringing in a CD226 antibody from the Spanish biotech IMIDomics.
My latest for @endpts.com: endpoints.news/exclusive-fo...
Exclusive: Formation Bio has licensed its first drug since raising $372M — an anti-CD226 antibody from IMIDomics — and plans two more deals in 2025 as it builds out its pipeline.
Exclusive: Formation licenses first drug since $372M raise, eyes more deals in 2025
Formation Bio licenses first-in-class anti-CD226 antibody from IMIDomics for IBD treatment, marking first drug acquisition since $372M Series D raise in 2023.
endpoints.news
July 29, 2025 at 5:43 PM
Exclusive: Formation Bio has licensed its first drug since raising $372M — an anti-CD226 antibody from IMIDomics — and plans two more deals in 2025 as it builds out its pipeline.
Formation Bio Expands Its Immunology Portfolio with New Anti-CD226 License Agreement#USA#New_York#Formation_Bio#IMIDomics#Anti-CD226
Formation Bio Expands Its Immunology Portfolio with New Anti-CD226 License Agreement
Formation Bio has secured a license for IMIDomics' first-in-class anti-CD226 monoclonal antibody, targeting autoimmune diseases like ulcerative colitis, promising a new treatment avenue.
third-news.com
July 29, 2025 at 2:32 PM
Formation Bio Expands Its Immunology Portfolio with New Anti-CD226 License Agreement#USA#New_York#Formation_Bio#IMIDomics#Anti-CD226
#PCBCommunity |📢 La biotecnològica #IMIDomics signa un acord de llicència mundial amb la farmacèutica #FormationBio pel desenvolupament del seu programa #first-in-class d’anticòs monoclonal #anti-CD226, obrint la porta a noves opcions terapèutiques per les #MalaltiesAutoimmunes. 🛡️
👉 tuit.cat/0btiq
👉 tuit.cat/0btiq
July 30, 2025 at 12:02 PM
#PCBCommunity |📢 La biotecnològica #IMIDomics signa un acord de llicència mundial amb la farmacèutica #FormationBio pel desenvolupament del seu programa #first-in-class d’anticòs monoclonal #anti-CD226, obrint la porta a noves opcions terapèutiques per les #MalaltiesAutoimmunes. 🛡️
👉 tuit.cat/0btiq
👉 tuit.cat/0btiq
Belgium: UCB strengthens in IMIDs with acquisition of IMIDomics’ Patient Insight business
https://www.byteseu.com/1985158/
Euronext-listed UCB, a Belgium-based global biopharmaceutical company focused on severe neurological and immunological conditions, has acquired the Patients Insights …
https://www.byteseu.com/1985158/
Euronext-listed UCB, a Belgium-based global biopharmaceutical company focused on severe neurological and immunological conditions, has acquired the Patients Insights …
Belgium: UCB strengthens in IMIDs with acquisition of IMIDomics’ Patient Insight business - Bytes Europe
Euronext-listed UCB, a Belgium-based global biopharmaceutical company focused on severe neurological and immunological conditions, has acquired the Patients
www.byteseu.com
May 2, 2026 at 10:26 PM
Belgium: UCB strengthens in IMIDs with acquisition of IMIDomics’ Patient Insight business
https://www.byteseu.com/1985158/
Euronext-listed UCB, a Belgium-based global biopharmaceutical company focused on severe neurological and immunological conditions, has acquired the Patients Insights …
https://www.byteseu.com/1985158/
Euronext-listed UCB, a Belgium-based global biopharmaceutical company focused on severe neurological and immunological conditions, has acquired the Patients Insights …
Thoughts on this? >> Exclusive: Formation Bio licenses IMIDomics IBD drug >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #healthcare #pharmaceutical
Exclusive: Formation Bio licenses IMIDomics IBD drug
Formation Bio CEO Benjamine Liu has raised the cash to build the next big biotech company. Now, he just needs the drugs. On Tuesday, Formation took a step toward that goal, licensing its first molecule ...
dlvr.it
July 29, 2025 at 11:41 AM
Thoughts on this? >> Exclusive: Formation Bio licenses IMIDomics IBD drug >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #healthcare #pharmaceutical
UCB snaps up IMIDomics data unit to fuel precision medicine push firstwordhealthtech.com/story/7259217
Loading...
firstwordhealthtech.com
May 1, 2026 at 9:21 PM
UCB snaps up IMIDomics data unit to fuel precision medicine push firstwordhealthtech.com/story/7259217